The UK Dementia Research Institute is the UK’s single biggest investment in dementia research. Revolutionary in scale and scope, it will transform dementia research in the UK.
The UK Dementia Research Institute (UK DRI) is a joint £250 million investment from the Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK.
Collaboration and idea sharing between world-leading researchers across the institute and globally underpin how we work and will accelerate our understanding of dementia. Our work will benefit people with all types of dementia—providing better and faster ways to diagnose, treat, prevent and care. The UK DRI will partner with the biopharma and technology sectors in order to stimulate translation of institute findings into new treatments, preventions and care approaches for dementia.
The UK DRI at King’s College London will build on the College's world-class basic and clinical neuroscience research that drives a strong translational mission for neurodegenerative disorders. King’s has a long track record of research excellence in dementia and neurodegeneration, from major discoveries in fundamental disease mechanisms through to large-scale clinical trials. Our contributions include the discovery of new genes, potential therapeutic targets, imaging and proteomic biomarkers, and our international leadership in clinical trials. The UK DRI at King's Colleg London focuses initially on FTD/ALS, making use of our strongest and most promising research. We will then expand the institute to explore the contributions of synucleinopathies and neuroinflammation to dementia, exploiting our strengths in immunology and developmental neuroscience and extending our collaborations with researchers in the MRC Centre for Neurodevelopmental Disorders and the Wolfson Centre for Age Related Diseases.